Neurenati Therapeutics, a Montreal, Québec, Canada-based biotech company dedicated to developing therapies for rare diseases, raised $1.38M in funding.
Quebec Government made the investment via its Impulsion PME program. Angels participated in the second close.
The company intends to use the funds to effectively advance NEU-001 toward clinical trials.
Led by CEO and President Maxime Ranger, Neurenati Therapeutics is a biotech company dedicated to developing therapies for rare diseases. The first technology targets Hirschsprung disease (HSCR), a life-threatening gastrointestinal (GI) birth defect characterized by the lack of nerves in parts of the lower GI tract.
NEU-001 is a proposed first-in-class therapy to treat Hirschsprung’s disease, a rare gastrointestinal disease affecting approximately 1,300 newborns in North America each year.
Neurenati still targets the end of 2025 to file a clinical trial application in Canada and the United States. Moreover, the company is always looking for other technologies in the field of rare diseases, especially in pediatrics.
FinSMEs
18/04/2024